InflaRx (IFRX) Total Non-Current Liabilities (2016 - 2026)
InflaRx's (IFRX) quarterly Total Non-Current Liabilities came in at $712532.2 in Q1 2026, up 103.83% year-on-year from $349563.3 in Q1 2025, and down 9.7% quarter-over-quarter from $789046.9 in Q4 2025.
InflaRx (IFRX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
InflaRx has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $712532.2 for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $712532.2, up 103.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $712532.2 (up 103.83% YoY), and the FY2025 annual result was $789046.9, up 69.38% from the prior year.
- Total Non-Current Liabilities came in at $712532.2 for Q1 2026 at InflaRx, down from $789046.9 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.3 million in Q2 2022 to a low of $272525.0 in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $842023.0 (2023), against an average of $811990.8.
- Across the five-year window, Total Non-Current Liabilities jumped 446.31% in 2022 and slumped 60.34% in 2025, its largest moves.
- InflaRx's Total Non-Current Liabilities stood at $1.0 million in 2022, then decreased by 19.42% to $842023.0 in 2023, then sank by 44.68% to $465846.7 in 2024, then soared by 69.38% to $789046.9 in 2025, then decreased by 9.7% to $712532.2 in 2026.
- The last three Total Non-Current Liabilities figures came in at $712532.2 (Q1 2026), $789046.9 (Q4 2025), and $861618.2 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 42,980.09 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 64.76 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 712,532.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 712,532.19 |
| Dec 31, 2025 | 789,046.90 |
| Sep 30, 2025 | 861,618.15 |
| Jun 30, 2025 | 272,524.95 |
| Mar 31, 2025 | 349,563.29 |
| Dec 31, 2024 | 465,846.68 |
| Sep 30, 2024 | 588,431.50 |
| Jun 30, 2024 | 687,131.81 |
| Mar 31, 2024 | 829,909.78 |
| Dec 31, 2023 | 842,023.04 |
| Sep 30, 2023 | 880,333.32 |
| Jun 30, 2023 | 927,150.52 |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 1.13 Mn |
| Jun 30, 2022 | 1.29 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 1.40 Mn |
| Jun 30, 2021 | 1.54 Mn |